---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-26-000054"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2026-08-13T20:07:52+00:00"
generated_at: "2026-08-13T20:10:22.701644+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# MacroGenics Q2 net income $19.5M; sells manufacturing to Bora for $122.5M, cash runway to 2028

## Summary
- Q2 2026 revenue $32.8M vs $6.9M YoY; net income $19.5M vs net loss $36.3M YoY, driven by $24.5M Sanofi TZIELD milestone and $89.2M discontinued ops gain.
- Completed sale of GMP manufacturing to Bora for $122.5M base price; received $119.6M cash at closing; workforce cut to ~140 employees.
- Pro forma cash $327M as of June 30, 2026 (incl. Bora, Sanofi, Gilead proceeds); cash runway guided through 2028.
- Gilead exercised option for preclinical bispecific program, triggering $10.0M payment; eligible for up to ~$2.4B in future milestones from partners.
- Pipeline: MGC026 SCCHN cohort met threshold to advance to Stage 2; MGC030 IND cleared, first patient Q3 2026; MGC028 update late 2026.

## SEC filing metadata
- accession: 0001125345-26-000054
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2026-08-13T20:07:52+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/0001125345-26-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534526000054/mgnx-20260813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-26-000054
- JSON: https://secwatch.observer/filing/0001125345-26-000054.json
- Plain text: https://secwatch.observer/filing/0001125345-26-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.